Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population

BMC Cancer

Mererid Evans²  Robert Newcombe⁵  Alison Fiander⁶  James Powell²  Martin Rolles⁴  Selvam Thavaraj¹  Max Robinson⁷  Ned Powell³ 

[1] Department of Clinical and Diagnostic Sciences, King’s College London Dental Institute, Strand, London, WC2R 2LS, UK

[2] Velindre Cancer Centre, Whitchurch, Cardiff, CF14 2TL, UK

[3] HPV Oncology Group, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

[4] Singleton Hospital, Sketty Lane, Swansea,, SA2 8QA, UK

[5] Department of Primary Care and Public Health, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

[6] Department of Obstetrics and Gynaecology, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

[7] Centre for Oral Health Research, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4BW, UK

关键词: Tonsil;    Prognosis;    Papillomavirus;    HPV;    Cancer;    Oropharynx;    Oropharyngeal;   

Others  :  1079771
DOI  :  10.1186/1471-2407-13-220

 received in 2013-01-21, accepted in 2013-04-25,  发布年份 2013

【 摘 要 】

Background

The incidence of Human Papillomavirus (HPV) associated oropharyngeal cancer (OPC) is increasing. HPV-associated OPC appear to have better prognosis than HPV-negative OPC. The aim of this study was to robustly determine the prevalence of HPV-positive OPC in an unselected UK population and correlate HPV positivity with clinical outcome.

Methods

HPV testing by GP5+/6+ PCR, In Situ Hybridisation (ISH) and p16 immunohistochemistry (IHC) was performed on 138 OPCs diagnosed in South Wales (UK) between 2001–06. Kaplan-Meier analysis was used to correlate HPV status with clinical outcome.

Results

Using a composite definition of HPV positivity (HPV DNA and p16 overexpression), HPV was detected in 46/83 (55%) samples where DNA quality was assured. Five year overall survival was 75.4% (95% CI: 65.2 to 85.5) in HPV-positives vs 25.3% (95% CI: 14.2 to 36.4) in HPV negatives, corresponding to a 78% reduction in death rate (HR 0.22, p < 0.001). HPV-positives had less locoregional recurrence but second HPV-positive Head and Neck primaries occurred. Poor quality DNA in fixed pathological specimens reduced both HPV prevalence estimates and the prognostic utility of DNA-based HPV testing methods. As a single marker, p16 was least affected by sample quality and correlated well with prognosis, although was not sufficient on its own for accurate HPV prevalence reporting.

Conclusions

This study highlights the significant burden of OPC associated with HPV infection. HPV positive cases are clinically distinct from other OPC, and are associated with significantly better clinical outcomes. A composite definition of HPV positivity should be used for accurate prevalence reporting and up-front DNA quality assessment is recommended for any DNA-based HPV detection strategy.

【 授权许可】

   
2013 Evans et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ahrlund-Richter S, Marklund L, Romanitan M, Lindquist D: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009, 125(2):362-366.
• [2]Junor EJ, Kerr GR, Brewster DH: Oropharyngeal cancer. Fastest increasing cancer in Scotland, especially in men. BMJ 2010, 340:c2512.
• [3]Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, Clark JR, Milross CG, Kim J, O'Brien CJ: Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010, 103(10):1510-1517.
• [4]Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
• [5]Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN: Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010, 16(4):1226-1235.
• [6]Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS: Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010, 2:15. BioMed Central Full Text
• [7]Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C: Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med 2010, 363(1):24-35.
• [8]Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100(4):261-269.
• [9]Mellin Dahlstrand H, Lindquist D, Bjornestal L, Ohlsson A, Dalianis T, Munck-Wikland E, Elmberger G: P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005, 25(6C):4375-4383.
• [10]Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008, 26(19):3138-3146.
• [11]Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantu G, Squadrelli M: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24(36):5630-5636.
• [12]Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, Woolgar JA, Helliwell TR, Triantafyllou A, Robinson M: Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011, 17(19):6262-6271.
• [13]Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH: A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007, 121(11):2465-2472.
• [14]Thavaraj S, Stokes A, Guerra E, Bible J, Halligan E, Long A, Okpokam A, Sloan P, Odell E, Robinson M: Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol 2011, 64(4):308-312.
• [15]Powell NG, Hibbitts SJ, Boyde AM, Newcombe RG, Tristram AJ, Fiander AN: The risk of cervical cancer associated with specific types of human papillomavirus: a case–control study in a UK population. Int J Cancer 2011, 128(7):1676-1682.
• [16]Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL: Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006, 24(5):736-747.
• [17]Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28(27):4142-4148.
• [18]Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, Cuschieri K: Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer 2012, 106(2):358-365.
• [19]Schache AG, Liloglou T, Risk JM, Jones TM, Ma XJ, Wang H, Bui S, Luo Y, Sloan P, Shaw RJ: Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J Cancer 2013, 108:1332-1339.
• [20]Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ: Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011, 22(5):1071-1077.
• [21]Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schepers M, Bot FJ, Hopman AH, Ramaekers FC, Speel EJ: Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008, 122(12):2656-2664.
• [22]Joseph AW, Ogawa T, Bishop JA, Lyford-Pike S, Chang X, Phelps TH, Westra WH, Pai SI: Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. Oral Oncol 2012, 49:244-8.
• [23]McGovern SL, Williams MD, Weber RS, Sabichi A, Chambers MS, Martin JW, Chao KS: Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field cancerization. Head Neck 2010, 32(8):1118-1124.
• [24]Singhi AD, Califano J, Westra WH: High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck 2012, 34(2):213-218.